Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, while removing the previous wording about those conducting the study.SummaryDifference2%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedSeveral key medical and genetic resource links have been removed, including those related to breast cancer and hormone information, which may impact access to important health information.SummaryDifference4%
- Check36 days agoChange DetectedThe website has added several new resources related to genetics and breast cancer, including links to MedlinePlus and DailyMed, as well as new data fields for study information, while updating the revision from v2.12.1 to v2.12.2.SummaryDifference4%
- Check50 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.1%
- Check57 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential enhancements or features.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.